Evaluation of insulin regimens as an effective option for glycemic control in patients with type 2 diabetes: A propensity score-matched cohort study across Japan (JDDM31)

Journal of Diabetes Investigation

Volumn 5, Issue 5, 2014, Pages 539-547

  Kanatsuka, Azuma ^a   Sato, Yasunori ^a   Kawai, Koichi ^b   Hirao, Koichi ^c   Kobayashi, Masashi ^d   Kashiwagi, Atsunori ^e   Abe, Nobuyuki ^f   Arai, Keiko ^f   Fujiya, Hiroshi ^f   Fukumoto, Yoshihide ^f   Dake, Fumihiko ^f   Iizumi, Tomohiro ^f   Ito, Masaaki ^f   Iwasaki, Koichi ^f   Kanamori, Akira ^f   Kato, Sumio ^f   Kato, Masakazu ^f   Kawara, Akira ^f   Kimura, Kenichi ^f   Chikamori, Kazumasa ^f   Iemitsu, Kotaro ^f   Kou, Shigetake ^f   Kudo, Mikihiko ^f   Kurihara, Yoshio ^f   Lee, Gendai ^f   Tsuruoka, Akira ^f   Manda, Naoki ^f   Matoba, Kiyokazu ^f   Hayashi, Hiroshi ^f   Minami, Masae ^f   Kuribayashi, Nobuichi ^f   Miyazawa, Kazuhiro ^f   Chiba, Yasuko ^f   Osonoi, Takeshi ^f   Nakamura, Shin ^f   Sasaki, Hideo ^f   Komori, Katsutoshi ^f   Oishi, Mariko ^f   Okada, Akira ^f   Okuguchi, Fuminobu ^f   Yanagisawa, Morifumi ^f   Sugimoto, Hidekatsu ^f   Sugiyama, Hiromichi ^f   Takai, Masahiko ^f   Takaki, Masato ^f   Takamura, Hiroshi ^f   Takeda, Hiroshi ^f   Tanaka, Kokichi ^f   Miwa, Takashi ^f   Tomonaga, Osamu ^f   Taguchi, Madoka ^f   Yamazaki, Katsuya ^f   Wada, Takako ^f   Yagi, Noriharu ^f   Yamaoka, Kuniko ^f   Yuhara, Atsuyoshi ^f   more..

^a CHIBA UNIVERSITY   (Japan)

^b Kawai Clinic   (Japan)

^c HEC Science Clinic   (Japan)

^d Takaoka Social Insurance Hospital   (Japan)

^e SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^f NONE

Author keywords

Insulin regimens; Propensity score matched analysis; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LONG ACTING INSULIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG MIXTURE; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; JAPAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPENSITY SCORE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE;

EID: 84908566861     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12194     Document Type: Article

References (36)

1. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
2. Levy J, Atkinson AB, Bell PM, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-296.
3. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
4. Kahn SE, Haffner SM, Heise ME, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
5. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diab 2005; 23: 78-86.
6. Nahtan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
7. Brezel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycemic agents (APOLLO): an open randomized controlled trial. Lancet 2008; 371: 1073-1084.
8. Holman RP, Kerensa I, Thorne MS, et al. Addition of biphasic or prandial insulin aspart reduced HbA1c levels more than the addition of basal insulin detemir. N Engl J Med 2007; 357: 1716-1730.
9. Concato J, Shah N, Holwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.
10. Austin CP. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
11. Sato D, Sato Y, Masuda S, et al. Effects of a sitagliptin safety on prescription behavior for oral antihyperglycemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan. Drug Saf 2013; 36: 605-615.
12. Kanatsuka A, Kawai K, Hirao K, et al. The initiation of insulin therapy in type 2 diabetic patients treated with oral anti-diabetic drugs: an observational study in multiple institutes across Japan (JDDM 27) Diabetol Int 2012; 3: 164-173
13. Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan-A cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM1). Diabetes Res Clin Pract 2006; 73:198-204.
14. ®-based analysis of clinical data obtained at multiple institutions (JDDM 3). Diabetes Res Clin Pract 2006; 72: 277-283.
15. Yokoyama H, Kawai K, Oishi MJ, et al. Familial predisposition to cardiovascular risk and disease contributes to cardiovascular risk and disease interacting with other cardiovascular risk factors in diabetes-implication for common soil. Atherosclerosis 2008; 201: 332-338.
16. Committee of Japan Diabetes Society for the Diagnostic Criteria of Diabetes Mellitus. Report of the committee of Japan Diabetes Society on the classification and diagnosis of diabetes mellitus. J Jpn Diabetes Soc 1999; 42: 395-404 (Japanese).
17. Guideline Committee of the Japan Diabetes Society. Japan Diabetes Society guideline for the management of diabetes based on scientific evidences. Japan Diabetes Society, NankodoTokyo, 2010 (Japanese).
18. The Guideline for Epidemiology Study in Japan. The Ministry of Health, Labor and Welfare. June 30, 2003 (Japanese).
19. Tominaga M, Makino E, Yoshino G, et al. Report of the committee on standardization of laboratory testing related to diabetes mellitus: the seventh national survey on Hemoglobin A1c. J Jpn Diabetes Soc 2003; 46: 961-965 (Japanese).
20. American Diabetes Association. Clinical practice recommendations 1995. Diabetes Care 1995; 18(Suppl 1): 1-96.
21. UKPDS Group. UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 1994; 11: 534-544.
22. Seino Y, Nanjo K, Tajima N, et al. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
23. Kashiwagi A, Kasuga M, Araki E, et al. Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39-40.
24. Parsons LS. Reducing bias in a propensity score matched-pair sample using Greedy matching techniques. In: Proceedings of the Twenty-Sixth Annual SAS Users Groups International Conference, Long Beach, Calif., April 22-25, 2001, Cary, N.C.: SAS Institute, 2001
25. Owens DR, Zinman B, Bolli GB. Insulin today and beyond. Lancet 2001; 358: 739-746.
26. Holman RR, Farmer AJ, Davis MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
27. Janka HU, Plewe G, Riddle M, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.
28. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
29. Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.
30. Yki-Jarvien H, Juurinen L, Alvarsson M, et al. Initiate insulin by aggressive titration and education (INITIATE) A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-1369.
31. Qayyum R, Bolen S, Maruthur N, et al. Systemic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008; 149: 549-559.
32. Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systemic review and meta-analysis. Diabetologia 2009; 52: 1991-2000.
33. Giugliano D, Mainorino MI, Bellastella G, et al. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes. Meta-analysis of randomized controlled trials. Diabetes Care 2011; 34: 510-517.
34. Inzucchi S, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
35. MacKee M, Britton A, Black N, et al. Interpreting the evidence: choosing between randomized and non-randomized studies. BMJ 1999; 319: 312-315.
36. Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effect of invasive cardiac management on AMI survival using propensity score and instrumental variable. JAMA 2007; 297: 278-285.